USPTO Art Unit 1632 Prosecution Statistics

Art Unit Information

Art Unit: 1632
Group: 1630
Tech Center: 1600
Total Cases: 10,829
Last Active: December 2024

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18999456TARGETING THE PVR AXIS USING CAR T CELL THERAPY AND COMBINATIONSDecember 2024June 2025Allow510NoNo
18904578ABSOLUTE PRECIPITATION OF EXOSOMES (APEX) ISOLATIONOctober 2024February 2025Allow410YesNo
18735079METHOD FOR ANALYZING CONTENT AND DISTRIBUTION OF MICROPLASTICS IN MARINE CNIDARIA ORGANISMSJune 2024January 2025Allow710NoNo
18660825TRANSGENIC CORYMay 2024May 2025Abandon1321YesNo
18589909UTERINE-DERIVED REGENERATIVE CELL COMPOSITIONS AND USES THEREOFFebruary 2024January 2025Allow1021YesNo
18442444Non-Human Animals Expressing Humanized CD3 ComplexFebruary 2024June 2025Allow1601YesNo
18437775METHODS AND COMPOSITIONS FOR THE PRODUCTION OF OLIGODENDROCYTE PROGENITOR CELLSFebruary 2024September 2024Allow710NoNo
18435757THREE-DIMENSIONAL MICROTISSUES WITH INTEGRATED MECHANICAL LOADINGFebruary 2024June 2025Allow1611YesNo
18413219MOUSE HAVING A HUMANIZED CLUSTER OF DIFFERENTIATION 47 GENEJanuary 2024April 2025Allow1511YesNo
18410576ABSOLUTE PRECIPITATION OF EXOSOMES (APEX) ISOLATIONJanuary 2024September 2024Allow810NoNo
18409695KIT FOR BREEDING A TGEV INFECTION RESISTANT PIG AND USE THEREOFJanuary 2024January 2025Allow1221YesNo
18395362SC-BETA CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAMEDecember 2023May 2024Allow510NoNo
18541448GENERATION OF ALVEOLAR EPITHELIAL TYPE 1 (AT1) CELLSDecember 2023February 2025Allow1421YesNo
18526758METHODS FOR TARGETED INSERTION OF DNA IN GENESDecember 2023December 2024Allow1310YesNo
18526745METHODS FOR TARGETED INSERTION OF DNA IN GENESDecember 2023April 2024Allow410YesNo
18524967GENE THERAPY FOR AADC DEFICIENCYNovember 2023June 2025Allow1910NoNo
18518212ABCA4 TRANS-SPLICING MOLECULESNovember 2023June 2025Allow1932YesNo
18562767AGENT FOR IMPROVING CANCER CACHEXIA AND METHOD FOR IMPROVING CANCER CACHEXIANovember 2023December 2024Abandon1310YesNo
18381652VASCULARIZED CARDIAC ORGANOID WITH A CHAMBER STRUCTURE AND ITS PREPARATION METHODOctober 2023September 2024Allow1110YesNo
18381660VASCULARIZED ISLET AND PREPARATION METHOD THEREOFOctober 2023February 2025Abandon1620NoNo
18371636FORMATION OF ARRAYS OF PLANAR INTESTINAL CRYPTS POSSESSING A STEM/PROLIFERATIVE CELL COMPARTMENT AND DIFFERENTIATED CELL ZONESeptember 2023September 2024Allow1120YesNo
18468820CRYOPROTECTIVE COMPOSITIONS AND USES THEREOFSeptember 2023May 2025Abandon2010NoNo
18468594OPTIMIZED EXPRESSION CASSETTES FOR GENE THERAPYSeptember 2023July 2024Allow1021YesNo
18231518SERUM-FREE AND XENO-FREE CULTURE MEDIUM FOR EXPANDING MESENCHYMAL STEM CELLSAugust 2023February 2025Allow1921YesNo
18363453CNS GENE DELIVERY USING PERIPHERAL ADMINISTRATION OF AAV VECTORSAugust 2023March 2025Allow1910YesNo
18226877METHODS OF GENERATING A SYNTHETIC EMBRYOJuly 2023February 2024Allow610NoNo
18356029RECOMBINOGENIC NUCLEIC ACID STRANDS IN SITUJuly 2023January 2024Allow610NoNo
18223865COHESIVE THIN LIQUIDS TO PROMOTE SAFE SWALLOWING IN DYSPHAGIC PATIENTSJuly 2023February 2025Allow1920NoNo
18223733EXTENSIONAL VISCOSITY TO PROMOTE SAFE SWALLOWING OF FOOD BOLUSESJuly 2023February 2025Allow1920NoNo
18271677SIMULATION METHOD FOR CHRONIC ATROPHIC GASTRITIS (CAG) LESION AND IDENTIFICATION METHOD FOR MOUSE MODELINGJuly 2023May 2025Abandon2220NoNo
18347487CHIMERIC ANTIGEN RECEPTOR COMPRISING BCMA NANOBODY LINKED TO A CHIMERIC INTRACELLULAR SIGNALING DOMAINJuly 2023August 2024Allow1312YesNo
18337454TIL EXPANSION PROCESSES USING SPECIFIC CYTOKINE COMBINATIONS AND/OR AKTI TREATMENTJune 2023February 2024Allow810YesNo
18210821DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLSJune 2023May 2025Abandon2310NoNo
18335001METHODS AND COMPOSITIONS FOR MANUFACTURING EXTRACELLULAR MATRIXJune 2023April 2025Abandon2201NoNo
18332620METHODS AND PRODUCTS FOR TRANSFECTING CELLSJune 2023March 2025Allow2210NoNo
18332621METHODS AND PRODUCTS FOR TRANSFECTING CELLSJune 2023April 2025Allow2210NoNo
18328473SWITCH RECEPTORS USING IL-9 SIGNALING DOMAINSJune 2023September 2024Allow1621NoNo
18325321IMPORTATION OF MITOCHONDRIAL PROTEIN BY AN ENHANCED ALLOTOPIC APPROACHMay 2023January 2025Abandon2010NoNo
18319677METHODS FOR EXPANDING AND ACTIVATING yo T CELLS FOR THE TREATMENT OF CANCER AND RELATED MALIGNANCIESMay 2023June 2025Allow2510YesNo
18316688RECOMBINANT CONSTRUCTS AND TRANSGENIC FLUORESCENT ORNAMENTAL FISH THEREFROMMay 2023February 2025Allow2120NoNo
18312538Methods Of Treating Non-Arteritic Anterior Ischemic Optic NeuropathyMay 2023January 2024Allow921YesNo
18139063USE OF PHOTOSYNTHETIC SCAFFOLDS IN TISSUE ENGINEERINGApril 2023April 2025Allow2421YesNo
18137578METHOD AND APPARATUS FOR IMPROVED MESENCHYMAL STEM CELL HARVESTINGApril 2023September 2024Allow1720NoNo
18134892METHODS AND COMPOSITIONS FOR INDUCING TUMOR CELL DEATHApril 2023October 2024Abandon1801NoNo
18300693Liver-Specific Nucleic Acid Regulatory Elements and Methods and Use ThereofApril 2023May 2025Allow2510NoNo
18134095ANTI-VEGF ANTIBODY CONSTRUCTSApril 2023June 2025Allow2641YesNo
18296779CORTICAL INTERNEURONS AND OTHER NEURONAL CELLS PRODUCED BY THE DIRECTED DIFFERENTIATION OF PLURIPOTENT AND MULTIPOTENT CELLSApril 2023September 2024Allow1711NoNo
18124921NEURAL TISSUE UNIT AND USE OF SUCH A UNIT FOR IMPLANTATION INTO THE NERVOUS SYSTEM OF A MAMMALMarch 2023June 2025Allow2741YesNo
18187268TRANSDUCED T CELLS EXPRESSING HUMAN SSTR2 AND APPLICATION THEREOFMarch 2023February 2025Allow2320NoNo
18122180SYSTEM AND METHOD FOR MONITORING THE HEALTH OF DIALYSIS PATIENTSMarch 2023May 2025Allow2621YesNo
18119682CULTURE MEDIUM, COATING MATRIX AND METHOD FOR EXPANDING MIDBRAIN DOPAMINERGIC PROGENITOR CELLSMarch 2023August 2024Allow1721YesNo
18119692CULTURE MEDIUM, COATING MATRIX AND METHOD FOR MATURING MIDBRAIN DOPAMINERGIC PROGENITOR CELLSMarch 2023March 2025Allow2442NoNo
18179814SIMULTANEOUS SPATIO-TEMPORAL MEASUREMENT OF GENE EXPRESSION AND CELLULAR ACTIVITYMarch 2023October 2023Allow710NoNo
18115283Methods of Producing Specialized Cardio-Like Cells from Stem CellsFebruary 2023February 2025Abandon2310NoNo
18110276HUMANIZED LIGHT CHAIN MICEFebruary 2023June 2025Allow2810NoNo
18166503HLA-F-MODIFIED CELLS AND METHODSFebruary 2023April 2024Allow1421YesNo
18166813Animal Models and Therapeutic MoleculesFebruary 2023June 2025Abandon2810NoNo
18106972Retroviral VectorFebruary 2023January 2025Allow2341YesYes
18161246CELL-CONTROLLED PERFUSION IN CONTINUOUS CULTUREJanuary 2023September 2024Allow1911NoNo
18160825TARGETED REPLACEMENT OF ENDOGENOUS T CELL RECEPTORSJanuary 2023June 2025Allow2910NoNo
18159725METHOD FOR GENERATING MESODERM AND/OR ENDOTHELIAL COLONY FORMING CELL-LIKE CELLS HAVING IN VIVO BLOOD VESSEL FORMING CAPACITYJanuary 2023November 2024Abandon2211NoNo
18099852METHODS FOR MAKING INSULIN IN VIVOJanuary 2023June 2025Allow2910YesNo
18156205ASSAY FOR DRUG DISCOVERY BASED ON IN VITRO DIFFERENTIATED CELLSJanuary 2023March 2025Allow2610YesNo
18004764RECIPROCATING PRESSURE PERFUSION SYSTEM AND METHODSJanuary 2023June 2025Allow2941YesNo
18093860A COMPOSITION COMPRISING NICOTINAMIDE MONONUCLEOTIDE AND LEUCOMETHYLENE BLUEJanuary 2023January 2025Abandon2431YesNo
18147554HEMATOPOIETIC STEM AND PROGENITOR CELLS DERIVED FROM HEMOGENIC ENDOTHELIAL CELLS BY EPISOMAL PLASMID GENE TRANSFERDecember 2022July 2024Allow1820YesNo
18002828METHODS FOR DERIVING DOPAMINERGIC NEURONS FROM PLURIPOTENT STEM CELLSDecember 2022May 2024Allow1721YesNo
18083912CELLULAR MICROCOMPARTMENT AND PREPARATION PROCESSESDecember 2022July 2024Allow1910YesNo
18068056GENE-EDITED NATURAL KILLER CELLSDecember 2022March 2025Allow2710YesNo
18082907REGENERATIVE CELL THERAPY FOR VIRAL INDUCED SEXUAL DYSFUNCTIONDecember 2022November 2024Abandon2311NoNo
18081476RETINAL PIGMENT EPITHELIUM CELL COMPOSITIONSDecember 2022January 2025Abandon2531YesNo
18064441AGENT FOR ACCELERATING GROWTH OF PLURIPOTENT STEM CELLSDecember 2022February 2025Allow2720YesNo
18077938METHODS OF TREATING CANCER USING NK CELLSDecember 2022November 2024Allow2330NoNo
17993674UNIVERSAL DONOR STEM CELLS AND RELATED METHODSNovember 2022March 2024Allow1611YesNo
17993667UNIVERSAL DONOR STEM CELLS AND RELATED METHODSNovember 2022March 2024Allow1611YesNo
17993680UNIVERSAL DONOR STEM CELLS AND RELATED METHODSNovember 2022March 2024Allow1611YesNo
17993659UNIVERSAL DONOR STEM CELLS AND RELATED METHODSNovember 2022October 2024Allow2311NoNo
18058457ADENO-ASSOCIATED VIRUS VECTORS ENCODING MODIFIED G6PC AND USES THEREOFNovember 2022June 2025Allow3020YesNo
18056145CANINE-SPECIFIC THERAPEUTIC COMPOSITIONS AND METHODS OF USENovember 2022June 2024Allow1921YesNo
18055312STEM CELL DERIVED ISLET DIFFERENTIATIONNovember 2022November 2023Allow1221YesNo
18055327STEM CELL DERIVED ISLET DIFFERENTIATIONNovember 2022August 2024Allow2120NoNo
17985746METHODS OF ENHANCING STEM CELL DIFFERENTIATION INTO BETA CELLSNovember 2022February 2024Abandon1520YesNo
18053165METHODS FOR GENERATING CELL SPHEROIDSNovember 2022December 2024Abandon3521NoNo
17982209METHODS AND COMPOSITIONS FOR TREATMENT OF A GENETIC CONDITIONNovember 2022February 2025Abandon2801NoNo
17980820KIDNEY ORGANOIDS AND METHOD FOR PRODUCING THE SAMENovember 2022June 2025Allow3130NoNo
17978936SC-BETA CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAMENovember 2022May 2023Allow710YesNo
18049266COMPOSITIONS AND METHODS FOR THERAPEUTIC DELIVERYOctober 2022February 2024Allow1631YesNo
17971677MEDIA FOR CULTURING STEM CELLSOctober 2022May 2025Allow3110YesNo
17969254GENETICALLY MODIFIED NON-HUMAN ANIMALS WITH COMMON LIGHT CHAIN IMMUNOGLOBULIN LOCUSOctober 2022March 2024Allow2721YesNo
18047673TRANSGENIC MICEOctober 2022May 2025Abandon3001NoNo
17968675DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLSOctober 2022March 2025Abandon2910NoNo
18047014HUMANIZED IL-15 ANIMALSOctober 2022March 2025Allow2911YesNo
17965257CUSTOM AUTOLOGOUS VACCINE COMPOSITION, AND A METHOD FOR ITS MANUFACTUREOctober 2022March 2025Abandon2950YesNo
17960047REDUCTION OF NEUTROPHIL EXTRACELLULAR TRAP FORMATION BY MESENCHYMAL STEM CELLS AND THEIR EXOSOMESOctober 2022August 2024Abandon2211NoNo
17958816METHODS AND PRODUCTS FOR TRANSFECTIONOctober 2022July 2024Allow2210NoNo
17958234CELL CULTURE SUBSTRATES, METHODS AND USES THEREOFSeptember 2022May 2023Allow820NoNo
17916308DUAL AAV-MYO7A VECTORS WITH IMPROVED SAFETY FOR THE TREATMENT OF USH1BSeptember 2022March 2025Allow3031YesNo
17957598THERAPY FOR POLYGLUTAMINE (POLYQ) DISEASESSeptember 2022March 2024Allow1710NoNo
17953216PREPARATION, EXPANSION, AND USES OF ADULT PLURIPOTENT STEM CELLSSeptember 2022September 2024Allow2321YesNo
17935135COMPOSITION AND METHODS FOR PRODUCING ADULT LIVER ORGANOIDSSeptember 2022July 2025Abandon3340NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1632.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
145
Examiner Affirmed
95
(65.5%)
Examiner Reversed
50
(34.5%)
Reversal Percentile
59.5%
Higher than average

What This Means

With a 34.5% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
1415
Allowed After Appeal Filing
284
(20.1%)
Not Allowed After Appeal Filing
1131
(79.9%)
Filing Benefit Percentile
6.2%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 20.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1632 - Prosecution Statistics Summary

Executive Summary

Art Unit 1632 is part of Group 1630 in Technology Center 1600. This art unit has examined 10,829 patent applications in our dataset, with an overall allowance rate of 47.1%. Applications typically reach final disposition in approximately 38 months.

Comparative Analysis

Art Unit 1632's allowance rate of 47.1% places it in the 5% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1632 receive an average of 2.36 office actions before reaching final disposition (in the 85% percentile). The median prosecution time is 38 months (in the 10% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With more office actions than average, plan for multiple rounds of prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.